Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is impli
'/>"/>

SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
(Date:1/22/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a ... cardiovascular disease and overall health is pleased to provide you ... its outlook for 2015 from the CEO, Mr. Eugene ... would like to take this opportunity to share with you ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity ... Mutations - (1,2)-The First Presentation of Data on BIBF ... Ingelheim will present new data on the company,s two ... the 2009 Annual Meeting of the American Society of ...
... TYRX, Inc., a leader in the ... the 30th Annual Scientific Sessions of the Heart ... its AIGISRX(TM) Antibacterial Envelope Retrospective Registry.AIGIS is an ... that help provide protection against infections associated with ...
Cached Medicine Technology:Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 2TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 3TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 4TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 5TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 6
(Date:1/22/2015)... 2015 Liberty University has received accreditation for ... from the Council for Accreditation of Counseling & Related ... Center for Counseling & Family Studies , is under ... university’s new School of Behavioral Sciences. Prior to the formation ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... seniors first diagnosed in childhood , , WEDNESDAY, Nov. 14 (HealthDay News) ... he still remembers the day he was first diagnosed with type ... at five years of age, and I thought to myself, ,OK, ... before, I just thought that,s where you went to die," said ...
... Mylan Inc. (NYSE: MYL ),announced that ... 1.86,million shares of 6.50% mandatory convertible preferred stock ... shares of common stock at $14,per share pursuant ... Securities and Exchange Commission. The underwriters have options ...
... solution frees pharmacy staff to focus on ... direct patient ... 14, Omnicell, Inc. (Nasdaq: OMCL ), a leading provider,of ... leading healthcare provider, today announced the successful,installation of the Omnicell ...
... Delta Dental, the nation,s,largest and most experienced ... Benefits Selling magazine as the dental benefits carrier,offering ... The,awards were announced in the November 2007 issue ... readers annually, asking them to vote on,company and ...
... ... with Diabetes, MIAMI, Nov. ... School of Medicine is joining,the International Diabetes Federation, the United Nations ... Day on,Wednesday, November 14, 2007, and to help raise awareness about ...
... CHICAGO, Nov. 13 Medicus Insurance Company today ... despite a,Cook County Circuit Court ruling overturning the ... awards for non-economic damages. "Today,s ruling hasn,t ... in,Illinois for years to come," Sheldon Davidow, President ...
Cached Medicine News:Health News:A Full and Long Life, Despite Diabetes 2Health News:A Full and Long Life, Despite Diabetes 3Health News:A Full and Long Life, Despite Diabetes 4Health News:Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock 2Health News:Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock 3Health News:Hendricks Regional Health Increases Patient Safety and Pharmacy Efficiency With Omnicell WorkflowRx 5.0 2Health News:Hendricks Regional Health Increases Patient Safety and Pharmacy Efficiency With Omnicell WorkflowRx 5.0 3Health News:Brokers Name Delta Dental the Best in Coverage, Plan Design and Networks 2Health News:Diabetes Research Institute Unites with Global Diabetes Community to Recognize World Diabetes Day 2Health News:Diabetes Research Institute Unites with Global Diabetes Community to Recognize World Diabetes Day 3Health News:New Med Mal Insurance Company Medicus to Stay in Illinois 2
Hartman Mosquito forceps, straight, 3-1/2", Sklarlite XD...
Hartman Mosquito forceps, straight, 3.5"....
Straight 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 3.9 inches...
Curved 21 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 4.7 inches...
Medicine Products: